

2021 status changes to the Basic and High Performance Formularies

Basic Formulary		
Preferred-to-nonpreferred changes, effective January 1, 2021		
ALREX	AVASTIN	BEPREVE
CARAC	COSENTYX	CRINONE
EPIDUO FORTE	FIASP	FIRST-LANSOPRAZOLE
FIRST-MOUTHWASH	FIRST-OMEPRAZOLE	FLUTICASONE-SALMETEROL
HERCEPTIN	HIZENTRA VIALS	ILEVRO
NEXIUM 2.5 MG, 5 MG	NOVOLIN, RELION	NOVOLOG
NUCYNTA	NUCYNTA ER	OGIVRI
ORACEA	PRALUENT	PRIVIGEN
PROAIR HFA	PROAIR RESPICLICK	PROLENSA
PYLERA	QBREXZA	ranitidine syrup
RITUXAN, RITUXAN HYCELA	TRUXIMA	UTIBRON NEOHALER